REMUUN AG

On-demand monoclonal antibody development.

The development of monoclonal antibody (mAb) therapies is a cornerstone of modern medicine, revolutionizing treatment across diverse disease areas. The field has a market value of CHF 300 billion per annum:
Problem: Current antibody development is slow, expensive, and limits therapeutic potential. Understanding and harnessing the natural antibody editing mechanism (AID) could revolutionize this process.
Solution: We've developed MEGA, the first modular AID-base editor. It mimics the full power of natural antibody gene modification, opening doors for faster, cheaper, and highly targeted antibody therapies.
Proof: We've already optimized a clinical-grade antibody in just one week; a feat impossible with traditional methods.
Value Proposition: Imagine new mAb therapies fast & precisely.

Only registered users have access to funding information.
Please log in or register to continue. Registration is free.

No news

No milestones

No Jobs

No videos and documents

Venture Kick

Venture Kick supports potential entrepreneurs with start capital up to CHF 150'000 as well as hands-on execution support and access to a nationwide network of investors and experts in the startup field. Multiple times per year, 8 selected projects get the opportunity to present their business ideas in front of a panel. The 5 most promising projects enter the support process. After 9 months at the latest, the startups incorporate and enter the market. Since 2007, Venture Kick has invested over CHF 58 million in over 1111 projects.

Venture Kick (150'000) 2025

Website